We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Genome-wide Association Study Identifies New Bipolar Disorder Loci

By LabMedica International staff writers
Posted on 13 May 2019
Print article
Image: Brain imaging studies have revealed differences in the volume of various brain regions between patients with bipolar disorder and healthy control subjects (Photo courtesy of Wikimedia Commons).
Image: Brain imaging studies have revealed differences in the volume of various brain regions between patients with bipolar disorder and healthy control subjects (Photo courtesy of Wikimedia Commons).
Results obtained by a large genome-wide association study performed on individuals with bipolar disorder identified 20 new genetic associations involving genes encoding ion channels, neurotransmitter transporters, and synaptic components.

Bipolar disorder, previously known as manic depression, is a mental disorder affecting approximately 60 million people worldwide that causes periods of depression and periods of abnormally elevated mood. The risk of suicide among those with the illness is high at greater than 6% over 20 years, while self-harm occurs in 30-40%. The causes of the disorder are not clearly understood, but both environmental and genetic factors play a role. Many genes of small effect contribute to risk. Environmental risk factors include a history of childhood abuse and long-term stress.

The condition is classified as bipolar I disorder if there has been at least one manic episode, with or without depressive episodes, and as bipolar II disorder if there has been at least one hypomanic episode (but no manic episodes) and one major depressive episode. Bipolar I disorder is strongly genetically correlated with schizophrenia, driven by psychosis, whereas bipolar II disorder is more strongly correlated with major depressive disorder.

To identify genes associated with bipolar disorder, investigators at the Mount Sinai School of Medicine (New York, NY, USA) and at more than 200 collaborating institutions performed a genome-wide association study (GWAS) including 20,352 cases and 31,358 controls of European descent, with follow-up analysis of 822 gene loci in an additional 9,412 cases and 137,760 controls.

Analysis of the results revealed 30 loci that were significant genome-wide, including 20 newly identified loci. The significant loci contained genes encoding ion channels, neurotransmitter transporters, and synaptic components. Pathway analysis revealed nine significantly enriched gene sets, including those regulating of insulin secretion and endocannabinoid signaling. Eight of the genes linked to bipolar disorder harbored schizophrenia associations as well.

"The crux of this international collaborative study was, in essence, to connect the dots," said first author Dr. Eli Stahl, assistant professor of genetics and psychiatry at Mount Sinai School of Medicine. "By discovering new genes associated with bipolar disorder and demonstrating their overlap with genes found in other psychiatric disorders, we bring ourselves closer to finding the true genetic underpinnings of the disease and improving patient outcomes."

The bipolar disorder GWAS paper was published in the May 1, 2019, online edition of the journal of Nature Genetics.

Related Links:
Mount Sinai School of Medicine

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Unstirred Waterbath
HumAqua 5
New
Chlamydia Trachomatis Assay
Chlamydia Trachomatis IgG

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.